"10.1371_journal.pone.0134703","plos one","2015-08-07T00:00:00Z","Alice B Gottlieb; James G Krueger; Mia Sandberg Lundblad; Marie Göthberg; Brett E Skolnick","Department of Dermatology, Tufts Medical Center, Boston, MA, United States of America; Department of Dermatology, Tufts University School of Medicine, Boston, MA, United States of America; The Rockefeller University, New York, NY, United States of America; Clinical Pharmacology, Novo Nordisk A/S, Søborg, Denmark; Medical-Science, Inflammation, Novo Nordisk Inc., Princeton, NJ, United States of America","Conceived and designed the experiments: ABG JGK MSL BES. Performed the experiments: ABG JGK. Analyzed the data: MSL MG BES. Contributed reagents/materials/analysis tools: JGK MSL BES. Wrote the paper: ABG JGK MSL MG BES.","The authors have the following interests: The study was funded by Novo Nordisk A/S, Denmark. Writing support was provided by Heather Heerssen, PhD, Jane Phillips, PhD, and Maryann Travaglini, PharmD, of Complete Healthcare Communications, Inc. (Chadds Ford, PA, USA). This support was funded by Novo Nordisk. A Gottlieb: Consulting/advisory board: Amgen Inc., Astellas, Akros, Centocor (Janssen), Inc., Celgene Corp., Bristol Myers Squibb Co., Beiersdorf, Inc., Abbott Labs. (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd., Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, GlaxoSmithKline, Xenoport, Catabasis, Sanofi Aventis; DUSA; Research/educational grants (paid to Tufts Medical Center): Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia, Merck, Xenoport. J Krueger: Consulting/advisory board: Abbvie, Akros, Amgen, Biogen-Idec, Bristol Meyers Squibb, Boehringer-Ingelheim, Centocor/Janssen, Celgene, Delenex, Dermira, Leo Pharma, Eli Lilly, GlaxoSmithKline, Glenmark, Merck, Novartis, Novo Nordisk, Pfizer, Xenoport. M Sandberg Lundblad: Employee and stockholder of Novo Nordisk. M Gothberg: Employee and stockholder of Novo Nordisk. B Skolnick: At the time of manuscript preparation, Dr Skolnick was an employee and stockholder of Novo Nordisk. He is now employed with Cushing Neuroscience Institute, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY. NNC0109-0012 has been patented; however, there are no products in development or marketed products to declare. This does not alter our adherence to all the PLoS ONE policies on sharing data and materials.","2015","08","Alice B Gottlieb","ABG",5,TRUE,4,2,3,5,TRUE,FALSE,FALSE,0,NA,FALSE
